[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study Commentaries: Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre Merck’s antiviral pill reduces hospitalization […]
The post [Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19. appeared first on Links Medicus.
Review: COVID-19 in older adults.
COVID-19 in older adults – Cleveland Clinic Journal of Medicine
The post Review: COVID-19 in older adults. appeared first on Links Medicus.
Transition to endemicity: Understanding COVID-19.
Transition to endemicity: Understanding COVID-19 – Cell Related: COVID will likely shift from pandemic to endemic — but what does that mean? Perspective | How Endemic COVID Becomes a Manageable Risk – “Businesses and schools must adapt, because the dual threat from the coronavirus and the flu will be too severe”.
The post Transition to endemicity: Understanding COVID-19. appeared first on Links Medicus.
Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19.
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients – Frontiers in Pharmacology Related: M-A: Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19 – According to this analysis, standard-dose prophylactic anticoagulation should be the […]
The post Another meta-analysis suggests standard-dose prophylactic anticoagulation is the best option for patients hospitalized with Covid-19. appeared first on Links Medicus.
International registry shows mortality after ECMO for patients with COVID-19 worsened during 2020.
Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry – The Lancet Commentaries: ECMO in COVID-19: do not blame the tool – The Lancet ECMO life support offers sickest COVID-19 patients a chance to survive, but a slimmer one than once thought – Michigan Medicine – University of Michigan […]
The post International registry shows mortality after ECMO for patients with COVID-19 worsened during 2020. appeared first on Links Medicus.
Supplement: Acute Respiratory Distress Syndrome.
Homepage: Acute Respiratory Distress Syndrome – Critical Care Clinics The Epidemiology of Acute Respiratory Distress Syndrome Before and After Coronavirus Disease 2019 Toward Optimal Acute Respiratory Distress Syndrome Outcomes Pathophysiology of Acute Respiratory Distress Syndrome and COVID-19 Lung Injury COVID-19–Associated Acute Respiratory Distress Syndrome Pathophysiology of the Acute Respiratory Distress Syndrome Acute Kidney Injury and […]
The post Supplement: Acute Respiratory Distress Syndrome. appeared first on Links Medicus.
Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom.
News release: Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom – University of Oxford Original study: Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19 – PLOS Medicine Commentaries: Two studies tie long COVID-19 to severe initial illness – CIDRAP Covid: 37% […]
The post Over a third of COVID-19 patients diagnosed with at least one long-COVID symptom. appeared first on Links Medicus.
[Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta.
Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest – Clover Biopharmaceutical Commentary: New Chinese vaccine could bolster global arsenal – Science
The post [Press release – Not published yet] Clover’s COVID-19 vaccine candidate demonstrates 79% efficacy against Delta. appeared first on Links Medicus.
Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection.
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine – New England Journal of Medicine Commentaries on Twitter In a phase 3 trial of the ChAdOx1 nCoV-19 vaccine in over 32,000 participants the incidence of serious adverse effects was low and the vaccine efficacy was 74%. Efficacy was documented in a range […]
The post Randomized trial with over 30.000 patients showed AstraZeneca vaccine was safe and resulted in 74% efficacy against symptomatic SARS-CoV-2 infection. appeared first on Links Medicus.
RCT: REGEN-COV antibody combination reduces hospitalizations in outpatients with Covid-19.
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19 – New England Journal of Medicine
The post RCT: REGEN-COV antibody combination reduces hospitalizations in outpatients with Covid-19. appeared first on Links Medicus.